PTO/SB/08A(10-01)
Approved for use through 10/31/2002, OMB 651-0031
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE
on of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 3

U	Complete if Known	equired to respond to a collection of information unless it contains a valid OMB control number	
	Application Number	09/623,922	
	Filing Date	August 31, 2001	
	First Named Inventor	Papadopoulos, Vassilios	
	Group Art Unit	1647	
	Examiner Name	Dang, Ian	
Attorney Docket No: 1941.017US1			

	US PATENT DOCUMENTS				
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate	

	FOREIGN PATENT DOCUMENTS				
Examiner Foreign Document No Initials*		Publication Date	Name of Patentee or Applicant of cited Document	T ²	
	WO-2007103162A2	09/13/2007	PAPADOPOULOS, V., et al.		
	WO-97018826A1	05/29/1997	Chang, C. C., et al.		

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		MEDLINE, ABSTRACT 91083838, 1 pg		
		Application Serial No. 09/762594 (Atty Ref 1941.015US1) Final Office Action		
		mailed 12-14-2004, 17	1	
		Application Serial No. 09/762594 (Atty Ref 1941.015US1) Non Final Office		
		Acton mailed 6-23-2004, 17 pgs		
		Application Serial No. 09-762594 (Atty Ref 1941.015US1) Notice of Allowance		
		mailed 8-30-2005, 4 pgs	<u> </u>	
		Application Serial No. 09/762594 (Atty Ref 1941.015US1) Response filed 9-23-		
		2004 to Non Final Office Action mailed 6-23-04, 15 pgs		
		Application Serial No. 11/331,940 (Atty Ref 1941.015US2) Preliminary		
		Amendment filed 1-13-06, 7 pgs	ļ	
		Application Serial No. 11/331,940 (Atty Ref 1941.015US2) Response to		
		Restriction Requirement filed 9-12-07, 7 pgs	<u> </u>	
		Application Serial No. 11/331,940 (Atty Ref 1941.015US3) Restriction		
	<u> </u>	Requirement mailed 6-12-07, 10 pgs	-	
		Australian Application No. 2004235618 Office Action dated 1-16-07, 3 pgs		
		Australian Application No. 2004203650 Non Final Office Action mailed 10-27-06, 8 pgs		
		Australian Application No. 2004203650 Response filed 6-7-07 to Non Final		
		Office Action mailed 10-27-06, 11 pgs		
		Australian Application No. 3096899 Office Action Response mailed 7-22-04, 5		
		pgs		
		Canadian Application No. 2327329 Office Action dated 1-17-07, 4 pgs		
		Canadian Application No. 2327329 Office Action dated 11-24-05, 5 pgs		
		Canadian Application No. 2327329 Response dated 5-19-06 to Office Action		
		dated 11-24-05, 16 pgs		
		Canadian Application No. 2339328 Office Action dated 2-5-07, 2 pgs	<u> </u>	
		Canadian Application No. 2339328 Office Action dated 5-11-06, 6 pgs		
		Canadian Application No. 2339328 Office Action Response dated 8-1-07 to		
		Office Action dated 5-17-06, 16 pgs		

EXAMINER DATE CONSIDERED

PTO/SB/08A(10-01)
Approved for use through 10/31/2002, OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
on of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE required to respond to a collection of information unless it contains a valid OMB control number
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	09/623,922
	Filing Date	August 31, 2001
i	First Named Inventor	Papadopoulos, Vassilios
	Group Art Unit	1647
	Examiner Name	Dang, Ian
Sheet 2 of 3	Attorney Docket No: 1	941.017US1

OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Canadian Application No. 2339328 Office Action Response dated 11-2-06 to	
		Canadian Office Action mailed 5-17-06, 7 pgs	
		European Application No 99 912 635.2 Office Action dated 3-12-04, 3 pgs	
		European Application No. 06076592.2 Communication dated 10-5-06, 1 pg	
		European Application No. 99 943 703.1 Office Action dated 10-21-05, 6 pgs	
		European Application No. 99 943 703.1 Office Action dated 4-13-05, 3 pgs	
		European Application No. 99 943 703.1 Communication dated 11-28-05	
		European Application No. 99 943 703.1 Response dated 5-23-06 to 11-28-05 Office Action, 3 pgs	
		European Application Serial No. 0607659.2 Extended European Search Report	
		and Communication dated 9-29-06.pdf, 9 pgs	
,		European Application Serial No. 0607659.2 Office Action dated 11-15-06, 3 pgs	
		European Application Serial No. 0607659.2 Office Action dated 7-20-07, 3 pgs	
		European Application Serial No. 0607659.2 Response dated 1-4-07, 9 pgs	
		International Search Report in PCT/US99/05853, 6 pgs	
		International Search Report in PCT/US99/03635, 6 pgs International Search Report in PCT/US99/18507 (8-9-07), 9 pgs	
		BRANCH, A., "A Good Antisense Molecule is Hard to Find", Trends Biochem	ļ
		Sci., 23(2), (Feb., 1998),45-50	
		CASALOTTI, S. O., et al., "Structure of the rat gene encoding the mitochondrial benzodiazepine receptor", Gene, 121(2), (Nov., 16, 1992),377-381	
		DON, J, et al., "Identification and characterization of the regulated pattern of expression of a novel mouse gene, meg1, during the meiotic cell cycle", <u>Cell Growth Differ.</u> , 3(8), (August 1992),495-505	
		DON, J., M. musculus mRNA megl, <u>Database EMBL [Online] AC X64455</u> , (02/21/1992),2 Pages	
		ELLIS, L. M., et al., "Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src", The Journal of Biological Chemistry, 273(2), (Jan. 9, 1998),1052-1057	
		GLENNEY, J. R., et al., "The sequence of human caveolin reveals identity with VIP21, a component of transport vesicles", <u>FEBS Lett., 314(1)</u> , (Dec. 7, 1992),45-8	
		LI, HUA, et al., "Identification, Localization, and Function in Steroidogenesis of PAP7: A Peripheral-Type Benzodiazepine Receptor- and PKA (RI?Ñ)-Associated Protein", Molecular Endocrinology 15(12), (2001),2211-2228	
		LU, C., et al., "Endogenous Interleukin 6 Can Function as an in Vivo Growthstimulatory Factor for Advanced-Stage Human Melanoma Cells", Clinical Cancer Research, 2(8), (1996),1417-1425	

DATE CONSIDERED

PTO/S8/084(10-01)
Approved for use through 10/31/2002, OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
on of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO	Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	09/623,922	
	Filing Date	August 31, 2001	
	First Named Inventor	Papadopoulos, Vassilios	
	Group Art Unit	1647	
	Examiner Name	Dang, Ian	
Sheet 3 of 3	Attorney Docket No: 1941.017US1		

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		MARRA, M., et al., mo98e12.rl Stratagene mouse testis (#937308) "Mus	
		musculus cDNA clone", <u>Database EMBL [Online] AC AA174581</u> , (Dec. 31,	ļ
		1996),2 Pages	
		PAWLIKOWSKI, M., et al., "Inhibition of Cell Proliferation of Human Gliomas by	
		Benzodiazepines in vitro", Acta Neurol Scand., 77(3), XP002114582,(Mar.	1
		1988),231-233	ļ
		RESNICOFF, M., et al., "Inhibition of rat C6 glioblastoma tumor growth by	
		expression of insulin-like growth factor I receptor antisense mRNA", Cancer	1
		Immunol. Immunother., 42(1), (1996),64-68	
		RUTKA, J. T., et al., "Effects of antisense glial fibrillary acidic protein	
		complementary DNA on the growth, invasion, and adhesion of human	
		astrocytoma cells", <u>Cancer Res., 54(12),</u> (June 15, 1994),3267-72	ļ
		SAMBROOK, J., et al., Molecular Cloning - a Laborary Manual, 2d Edition, Cold	
		Spring Laboratory Press,(1989),9.47-9.62	ļ
:		SHER, I, et al., "Mutations uncouple human fibroblast growth factor (FGF)-7	
	1	biological activity and receptor binding and support broad specificity in the	
		secondary receptor binding site of FGFs", <u>Journal of Biological Chemistry</u> ,	
		274(49), (December 3, 1999),35016-35022	
		WAKI, M., et al., "Antisense src expression inhibits U937 human leukemia cell	
		proliferation in conjunction with reduction of c-myb expression", Biochem	
	ļ	Biophys Res Commun., 201(2), (June 15, 1994),1001-7	
		WELLS, J. A., "Additivity of Mutational Effects in Proteins", <u>Biochemistry</u> , 29(37),	
L		American Chemical Soc.,(Sep. 18, 1990),8509-8517	1

EXAMINER DATE CONSIDERED